Oncology
FDA Grants Accelerated Approval to Tudriqev Plus Nivolumab for Advanced Melanoma After PD-1 Progression
The FDA granted accelerated approval to vusolimogene oderparepvec plus nivolumab for unresectable advanced melanoma progressing after PD-1 therapy, based on tumor response and response durability.
Dr. Abu Bakar · August 30, 2026 · 6 min